115308-98-0

115308-98-0 structure

Name: Tallimustine
Chemical Name: N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide
CAS Number: 115308-98-0
Molecular Formula: C₃₂H₃₈Cl₂N₁₀O₄
Molecular Weight: 697.61500
Catalog: API Antineoplastic agents Alkylating agent
Create Date: 2018-09-02 23:12:27
Modify Date: 2024-01-09 17:17:42
Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent[1][2][4].

Name	N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide
Synonyms	1H-Pyrrole-2-carboxamide,N-(5-(((3-amino-3-iminopropyl)amino)carbonyl)-1-methyl-1H-pyrrol-3-yl)-4-(((4-((4-(bis(2-chloroethyl)amino)benzoyl)amino)-1-methyl-1H-pyrrol-2-yl)carbonyl)amino)-1-methyl Tallimustine Tallimustine [INN]

Description	Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent[1][2][4].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Others >> Others
In Vitro	Tallimustine (0.1-10 μM, 4 h) induces damage to purified SV40 DNA[1]. Tallimustine (72 h ) shows cytotoxicity in CEM Cells, with an IC50 of 3.5 nM[1]. Tallimustine (25 and 100 nM, 6 days) induces erythroid differentiation of K562 cells[2]. Tallimustine (100 nM, 6 days) increases accumulation of γ-globin mRNA in K562 cells[2]. Tallimustine (0.5 μg/mL, 1 h) arrests SW626 cells in G2/M phase[3]. Cell Viability Assay[2] Cell Line: K562 cells Concentration: 25 and 100 nM Incubation Time: 4 days Result: Inhibited cell proliferation.
In Vivo	Tallimustine (3 mg/kg, i.p.) shows antileukaemic activity in L1210 tumor bearing mice[4]. Animal Model: L1210 tumor bearing mice[2]. Dosage: 3 mg/kg Administration: Intraperitoneal injection (i.p.) Result: Prolonged the survival of mice.